Difference between revisions of "Matt Fust"
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
==Description== | ==Description== | ||
| − | Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust. | + | Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Electra Therapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust. |
| + | |||
| + | ==See Also== | ||
| + | |||
| + | * [[LGBTQ Participants in Pharmaceutical, Vaccine and Biotech Studies]] | ||
==Further Reading/Research== | ==Further Reading/Research== | ||
Latest revision as of 22:57, 21 December 2023
Country
United States
Birth - Death
Occupation
Business
Description
Board member active in many companies in the Biotech field, including ArsenalBio, Altara Biotherapeutics, Electra Therapeutics, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceuticals. Senior Advisor for Out Leadership. From 2009 through 2013, he was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, culminating in the company’s sale to Amgen. He previously served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals (2003 – 2008), Chief Financial Officer of Perlegen Sciences (2002 – 2003), and Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Also known as Matthew Fust.
